Latest Breaking News On - Human immunology biosciences inc - Page 4 : comparemela.com

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐.

HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy

HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy

Felzartamab showed dose-dependent reduction in pathogenic antibody levels across two clinical studies Proteinuria remission observed across patient groups,.

Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing

/PRNewswire/ Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe.

DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results .